Kraig Biocraft Laboratories, Inc. (KBLB)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -3 | -4 | ||||||
| Net profit | $m | -5 | -8 | -4 | -3 | -3 | -4 | -4 | - |
| EPS reported | $ | -0.00 | -0.00 | ||||||
| Operating cashflow per share | $ | -0.00 | -1,640 | ||||||
| Capex per share | $ | 0.00 | 4.95 | ||||||
| FCF per share | $ | -0.00 | -1,645 | ||||||
| Free cash flow | $m | -2 | -1,794,365 | ||||||
| Net debt | $m | -0 | -2 | ||||||
| Book value equity | $m | -8 | -7 | ||||||
| Book value per share | $ | -0.01 | -0.01 | ||||||
| Number of shares | m | 1,059.49 | 1,110.34 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -11.32 | -13.42 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -50.48 | -0.00 | ||||||
| EV/EBITDA LTM | x | -29.88 | -26.00 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -4.00% | -4.04% | ||||||
| FCF Yield | % | -1.98% | -1980840.6% | ||||||
| Quality | |||||||||
| ROE | % | +45.30% | +50.38% | ||||||
| ROIC | % | +53.27% | +66.89% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.08 | -1,064,269.18 | ||||||
| Net Debt/EBITDA | x | 0.04 | 0.37 | ||||||
| EBIT/Net interest | x | -5.91 | -6.25 | ||||||
| Net debt/market cap | % | +1.65% | +1.49% | ||||||
| Net debt/Equity | x | 0.04 | 0.28 | ||||||
| Gross debt/equity | x | -0.21 | -0.25 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. The company’s products are used in performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, and other applications; military and police for its ballistic protection; and geotextiles, safe and protective clothing, textiles used in transportation and buildings, and functional and sportive textiles. Kraig Biocraft Laboratories, Inc. was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kraig Biocraft Laboratories, Inc. (KBLB)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. Its primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. The company’s products are used in performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, and other applications; military and police for its ballistic protection; and geotextiles, safe and protective clothing, textiles used in transportation and buildings, and functional and sportive textiles. Kraig Biocraft Laboratories, Inc. was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free